BRYNJELSEN SEAN
Known title: Chief Executive OfficerCIK: 0001669976
BRYNJELSEN SEAN's purchase track record
BRYNJELSEN SEAN has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/22/2022 | ETON | $21K | +37.3% | +86.2% | +5.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ETON | ▼ Sell | Open Market | 47,307 | $2.8M | 8/20/2026 | View on chart |
| ETON | ▼ Sell | Open Market | 36,373 | $2.2M | 8/20/2026 | View on chart |
| ETON | ▼ Sell | Open Market | 7,342 | $456K | 8/20/2026 | View on chart |
| ETON | ▼ Sell | Open Market | 8,978 | $562K | 8/19/2026 | View on chart |
| ETON | ▲ Buy | Option Exercise | 200,000 | $274K | 7/14/2026 | View on chart |
| ETON | ▲ Buy | Option Exercise | 27,500 | — | 7/12/2026 | View on chart |
| ETON | ▼ Sell | Open Market | 119,852 | $3.8M | 5/28/2026 | View on chart |
| ETON | ▼ Sell | Open Market | 148 | $5K | 5/28/2026 | View on chart |
| ETON | ▼ Sell | Tax Withholding | 5,015 | $77K | 1/1/2026 | View on chart |
| ETON | ▼ Sell | Tax Withholding | 6,732 | $113K | 12/12/2025 | View on chart |
| ETON | ▼ Sell | Open Market | 70,000 | $1.2M | 6/5/2025 | View on chart |
| ETON | ▼ Sell | Open Market | 70,000 | $1.2M | 6/4/2025 | View on chart |
| ETON | ▼ Sell | Open Market | 60,945 | $1.1M | 6/3/2025 | View on chart |
| ETON | ▼ Sell | Open Market | 8,655 | $159K | 6/3/2025 | View on chart |
| ETON | ▼ Sell | Open Market | 400 | $8K | 6/3/2025 | View on chart |
| ETON | ▲ Buy | Open Market | 10,000 | $21K | 9/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Eton Secures U.S. License for LIBERVANT Buccal Film
Eton Pharmaceuticals has signed an exclusive U.S. license and supply agreement with Aquestive Therapeutics for LIBERVANT, a buccal film designed to treat seizure clusters in epilepsy patients. The partnership will bring the product to market in April 2027, expanding Eton’s epilepsy portfolio. The deal positions Eton to capture a niche therapeutic area and could support future revenue growth.
Eton Secures U.S. License for LIBERVANT Buccal Film. Eton Pharmaceuticals has signed an exclusive U.S. license and supply agreement with Aquestive Therapeutics for LIBERVANT, a buccal film designed to treat seizure clusters in epilepsy patients. The partnership will bring the product to market in April 2027, expanding Eton’s epilepsy portfolio. The deal positions Eton to capture a niche therapeutic area and could support future revenue growth.